Effects of salmeterol fluticasone inhalation on pulmonary function and inflammatory cytokines in patients with acute exacerbation of chronic obstructive pulmonary disease

Abstract

Objective To investigate the effect of salmeterol fluticasone inhalation on pulmonary function and inflammatory cytokines in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods 110 patients with acute exacerbation of asthma combined with COPD were selected and divided into observation group (55 cases) and control group (55 cases) by the random number table.The control group was given conventional treatment, while the observation group was given salmeterol fluticasone inhalation therapy on the basis of routine treatment.The pulmonary function, inflammatory cytokines and curative effects were compared between the two groups. Results After treatment, the FVC, FEV1, FEV1/FVC of the observation group were (2.64±0.45)L, (1.98±0.46)L and (80.42±6.43)%, which were significantly better than those of the control group (t=2.89, 2.59, 6.27, all P<0.05), the improvement of lung function was more obvious than that of the control group (P<0.05). After treatment, the levels of TNF-α, IL-8, IL-10 and IL-17 in sputum of the observation group were (30.03±6.78)μg/L, (59.96±7.73)μg/L, (29.89±4.11)μg/L and (92.37±9.79)μg/L, respectively, which were significantly lower than those of the control group (t=7.54, 6.16, 7.04, 12.31, all P<0.05). After treatment, the levels of TNF-α, IL-8, IL-10 and IL-17 in peripheral blood of the observation group were (14.08±5.36)μg/L, (26.32±4.03)μg/L, (30.32±5.04)μg/L and (173.82±18.19)μg/L, respectively, which were significantly lower than those of the control group (t=4.26, 7.95, 11.25.5.31, all P<0.05). The decrease of inflammatory cytokines in sputum and peripheral blood of the observation group was more significant than that of the control group (P<0.05). The effective rate of the observation group was 94.55%, which was significantly higher than 81.82% of the control group (P<0.05). Conclusion Salmeterol fluticasone inhalation can improve patients' pulmonary function, decrease the level of inflammatory cytokines in sputum and peripheral blood, which is worthy of clinical application and spread. Key words: Asthma; Pulmonary disease, chronic obstructive; Pulmonary function; Inflammatory factor; Salmeterol fluticasone